News

Our latest news and updates!

June 30, 2025

Laverock Therapeutics expands seed funding and announces key milestone progress

Continue Reading
March 17, 2025

Laverock relocates to Tribeca development in London's Kings Cross, establishing expanded lab facilities to facilitate growth

Continue Reading
October 22, 2024

Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCT

Continue Reading
September 26, 2024

Laverock Therapeutics makes significant advances in its unique programmable gene silencing platform and announces pipeline focus on advanced therapies in oncology and genetic diseases

Continue Reading
September 5, 2024

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule

Continue Reading
March 26, 2024

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Continue Reading
November 20, 2023

Exploring the convergence of gene editing and RNAi in iPSC-derived allogeneic cell therapy

Continue Reading
October 30, 2023

Laverock Therapeutics secures Innovate UK award to advance immune effector cell therapeutics programme using GEiGS® technology

Continue Reading
October 20, 2023

Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at ESGCT

Continue Reading
October 2, 2023

Laverock Therapeutics to present at 2023 Cell & Gene Meeting on the Mesa

Continue Reading
September 28, 2023

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Continue Reading
May 15, 2023

Poster presentation demonstrates the differentiated profile and broad applicability of the company’s gene silencing platform

Continue Reading
August 31, 2022

Laverock Therapeutics founded to develop the next generation of programmable cell therapies

Continue Reading